person · Reporting owner

BARABE TIMOTHY C

Disclosed activity across 5 companies

Tapewire entity: 28773
SEC CIK: 0001237409

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Acer Therapeutics Inc.OPXA · Entity 108116	Director	November 18, 2016	November 22, 2016
Cartesian Therapeutics, Inc.RNAC · Entity 6015	Director	January 02, 2026	January 06, 2026
Heartflow, Inc.HTFL · Entity 3993	Director	July 22, 2026	July 24, 2026
VEEVA SYSTEMS INCVEEV · Entity 2124	Director	June 22, 2021	June 23, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Acer Therapeutics Inc.

Report date November 18, 2016 · Filed November 22, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,910	Ending reported balance After 2016-11-18 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2016-11-18 · Sale · Disposed 7,105 · Balance 20,719 Row 2 · 2016-11-18 · Sale · Disposed 7,809 · Balance 12,910
Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2018-04-08	Direct	0	Reported balance After 2016-11-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-18 · Sale · Disposed 16,000 · Balance 0

Cartesian Therapeutics, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	56,966	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 56,966 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01	Direct	7,800	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

Heartflow, Inc.

Report date July 22, 2026 · Filed July 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	188,231	Reported balance After 2026-07-22 transaction · row 1 1 source row Row 1 · 2026-07-22 · Exercise / conversion · Acquired 3,710 · Balance 188,231
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2035-08-07	Direct	15,000	Reported balance After 2026-07-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-22 · Exercise / conversion · Disposed 3,710 · Balance 15,000 F1: These stock options are fully exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: These stock options are fully exercisable.

VEEVA SYSTEMS INC

Report date June 22, 2021 · Filed June 23, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	6,643	Reported balance After 2021-06-22 transaction · row 1 1 source row Row 1 · 2021-06-22 · Exercise / conversion · Acquired 251 · Balance 6,643 F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-22 · Exercise / conversion · Disposed 251 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.

F3: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARQULE INC

Report date January 16, 2020 · Filed January 16, 2020

Section 16 reporting ended · disclosed 2020-01-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-16 transaction · row 1 1 source row Row 1 · 2020-01-16 · Other · Disposed 146,897 · Balance 0 F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2028-05-08	Direct	Reported balance After 2020-01-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.21 · Expires 2029-05-13	Direct	Reported balance After 2020-01-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2020-05-13	Direct	Reported balance After 2020-01-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2021-06-01	Direct	Reported balance After 2020-01-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2022-05-24	Direct	Reported balance After 2020-01-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2023-05-20	Direct	Reported balance After 2020-01-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2024-05-13	Direct	Reported balance After 2020-01-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2025-05-11	Direct	Reported balance After 2020-01-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2026-05-24	Direct	Reported balance After 2020-01-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2027-05-23	Direct	Reported balance After 2020-01-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 22, 2026 Filed Jul 24, 2026 22:40 UTC	Heartflow, Inc. HTFL · Entity 3993	Exercise / conversionStock Option · Derivative	3,710	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001464521-26-000109 · form4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 3,710 shares Expires 2035-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options are fully exercisable. Read SEC document
July 22, 2026 Filed Jul 24, 2026 22:40 UTC	Heartflow, Inc. HTFL · Entity 3993	Exercise / conversionCommon Stock	3,710	$19.00	$70,490.00	Disclosure SEC source: 0001464521-26-000109 · form4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 17, 2026 Filed Jul 20, 2026 22:18 UTC	Heartflow, Inc. HTFL · Entity 3993	Exercise / conversionStock Option · Derivative	5,000	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001464521-26-000105 · form4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,710 Underlying: Common Stock · 5,000 shares Expires 2035-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options are fully exercisable. Read SEC document
July 17, 2026 Filed Jul 20, 2026 22:18 UTC	Heartflow, Inc. HTFL · Entity 3993	Exercise / conversionCommon Stock	5,000	$19.00	$95,000.00	Disclosure SEC source: 0001464521-26-000105 · form4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 16, 2026 Filed Jun 18, 2026 21:31 UTC	Heartflow, Inc. HTFL · Entity 3993	GrantStock Option · Derivative	16,075	$32.05 Strike: $32.05	$515,203.75	Disclosure SEC source: 0001464521-26-000093 · form4.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,075 Underlying: Common Stock · 16,075 shares Expires 2036-06-16 F1 · derivative.exercise_date: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date. Read SEC document
March 11, 2026 Filed Mar 12, 2026 23:57 UTC	Heartflow, Inc. HTFL · Entity 3993	Exercise / conversionStock Option · Derivative	8,667	$0.00 Strike: $2.22	$0.00	Disclosure SEC source: 0001464521-26-000028 · form4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,412 Underlying: Common Stock · 8,667 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document
March 11, 2026 Filed Mar 12, 2026 23:57 UTC	Heartflow, Inc. HTFL · Entity 3993	Exercise / conversionCommon Stock	8,667	$2.22	$19,240.74	Disclosure SEC source: 0001464521-26-000028 · form4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 17, 2026 Filed Feb 20, 2026 00:14 UTC	Heartflow, Inc. HTFL · Entity 3993	Exercise / conversionStock Option · Derivative	2,497	$0.00 Strike: $8.33	$0.00	Disclosure SEC source: 0001464521-26-000022 · form4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,497 shares Expires 2032-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options are fully exercisable. Read SEC document
February 17, 2026 Filed Feb 20, 2026 00:14 UTC	Heartflow, Inc. HTFL · Entity 3993	Exercise / conversionCommon Stock	2,497	$8.33	$20,800.01	Disclosure SEC source: 0001464521-26-000022 · form4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:18 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $6.76	$0.00	Disclosure SEC source: 0001453687-26-000032 · wk-form4_1767734312.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2036-01-01 Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:18 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantCommon Stock	2,600	$0.00	$0.00	Disclosure SEC source: 0001453687-26-000032 · wk-form4_1767734312.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,966 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. Read SEC document
December 04, 2025 Filed Dec 8, 2025 21:07 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	30,000	$6.86	$205,797.00	Disclosure SEC source: 0001453687-25-000132 · wk-form4_1765228029.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,366 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.80 to $6.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
August 11, 2025 Filed Aug 12, 2025 01:00 UTC	Heartflow, Inc. HTFL · Entity 3993	ConversionConvertible Promissory Note · Derivative	131,578	$0.00 Strike: $15.20	$0.00	Disclosure SEC source: 0001628280-25-039731 · wk-form4_1754960446.xml · derivative · entry 3 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F1 · derivative.exercise_date: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F1 · derivative.expiration_date: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. Read SEC document
August 11, 2025 Filed Aug 12, 2025 01:00 UTC	Heartflow, Inc. HTFL · Entity 3993	ConversionCommon Stock	131,578	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-039731 · wk-form4_1754960446.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. Read SEC document
August 07, 2025 Filed Aug 12, 2025 01:00 UTC	Heartflow, Inc. HTFL · Entity 3993	GrantStock Option · Derivative	23,710	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001628280-25-039731 · wk-form4_1754960446.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,710 Underlying: Common Stock · 23,710 shares Expires 2035-08-07 F2 · derivative.exercise_date: The option will vest in full on the earlier of Heartflow's annual meeting of shareholders in 2026 and the first anniversary of the grant date, subject to continued service through such date. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $16.93	$0.00	Disclosure SEC source: 0001453687-25-000021 · wk-form4_1736198402.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2035-01-01 Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantCommon Stock	2,600	$0.00	$0.00	Disclosure SEC source: 0001453687-25-000021 · wk-form4_1736198402.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,366 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:41 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	7,500	$12.70	$95,250.00	Disclosure SEC source: 0001453687-24-000104 · wk-form4_1723668109.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,766 F1 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:06 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantStock Option (Right to Buy) · Derivative	228,000	$0.00 Strike: $0.66	$0.00	Disclosure SEC source: 0001453687-24-000023 · wk-form4_1704405997.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,000 Underlying: Common Stock · 228,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: This award will vest in 36 equal monthly installments, so that it shall be fully vested on January 2, 2027. Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:06 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantCommon Stock	178,000	$0.00	$0.00	Disclosure SEC source: 0001453687-24-000023 · wk-form4_1704405997.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,013 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:15 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	87,500	$0.93 Strike: $1.13	$81,375.00	Disclosure SEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 7 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2033-01-01 F7 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:15 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	Not disclosed Strike: $3.31	Not disclosed	Disclosure SEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 6 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F6 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F6 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:15 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	Not disclosed Strike: $4.01	Not disclosed	Disclosure SEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 5 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F5 · price: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. F5 · derivative.exercise_date: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:15 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	Not disclosed Strike: $3.00	Not disclosed	Disclosure SEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 4 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F4 · price: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. F4 · derivative.exercise_date: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:15 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $12.75	Not disclosed	Disclosure SEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 3 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-14 F3 · price: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. F3 · derivative.exercise_date: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:15 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	6,410	Not disclosed Strike: $17.47	Not disclosed	Disclosure SEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F2 · price: This option, which provided for vesting in full on June 14, 2018, was canceled in the Merger. F2 · derivative.exercise_date: This option, which provided for vesting in full on June 14, 2018, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:15 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	10,328	Not disclosed Strike: $11.00	Not disclosed	Disclosure SEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,328 shares Expires 2026-07-28 F1 · price: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on July 29, 2016, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. F1 · derivative.exercise_date: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on July 29, 2016, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. Read SEC document
January 02, 2023 Filed Jan 4, 2023 22:04 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	87,500	$0.00 Strike: $1.13	$0.00	Disclosure SEC source: 0001453687-23-000023 · wf-form4_167286983312515.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document
May 09, 2022 Filed May 11, 2022 20:21 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	50,000	$0.77	$38,720.00	Disclosure SEC source: 0001453687-22-000090 · wf-form4_165230048591024.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,013 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.77 to $0.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
January 14, 2022 Filed Jan 18, 2022 21:19 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$2.10 Strike: $2.10	$21,000.00	Disclosure SEC source: 0001453687-22-000036 · wf-form4_164254076389982.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document
January 14, 2022 Filed Jan 18, 2022 21:19 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	Exercise / conversionCommon Stock	10,000	$2.10	$21,000.00	Disclosure SEC source: 0001453687-22-000036 · wf-form4_164254076389982.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:31 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.31	$0.00	Disclosure SEC source: 0001453687-22-000015 · wf-form4_164141827353177.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 3, 2023. Read SEC document
August 18, 2021 Filed Aug 20, 2021 22:09 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	9,000	$4.00	$36,000.00	Disclosure SEC source: 0001453687-21-000105 · wf-form4_162949733485291.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,013 Read SEC document
June 22, 2021 Filed Jun 23, 2021 20:17 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	251	$0.00	$0.00	Disclosure SEC source: 0001628280-21-012732 · wf-form4_162447940243482.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
June 22, 2021 Filed Jun 23, 2021 20:17 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	251	$0.00	$0.00	Disclosure SEC source: 0001628280-21-012732 · wf-form4_162447940243482.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document
March 30, 2021 Filed Apr 1, 2021 22:28 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $4.01	$0.00	Disclosure SEC source: 0001453687-21-000044 · wf-form4_161731608492976.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F1 · derivative.exercise_date: This option vests in full on March 30, 2022. Read SEC document
March 26, 2021 Filed Mar 30, 2021 20:50 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	10,000	$4.10	$41,000.00	Disclosure SEC source: 0001453687-21-000037 · wf-form4_161713731929205.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,013 Read SEC document
March 25, 2021 Filed Mar 26, 2021 20:46 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	250	$0.00	$0.00	Disclosure SEC source: 0001209191-21-023225 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251 Underlying: Class A Common Stock · 250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
March 25, 2021 Filed Mar 26, 2021 20:46 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	250	$0.00	$0.00	Disclosure SEC source: 0001209191-21-023225 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document
December 25, 2020 Filed Dec 29, 2020 00:29 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	251	$0.00	$0.00	Disclosure SEC source: 0001209191-20-065262 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 501 Underlying: Class A Common Stock · 251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
December 25, 2020 Filed Dec 29, 2020 00:29 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	251	$0.00	$0.00	Disclosure SEC source: 0001209191-20-065262 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document
October 13, 2020 Filed Oct 15, 2020 20:35 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	SaleClass A Common Stock	1,292	$308.69	$398,827.48	Disclosure SEC source: 0001209191-20-054913 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,891 Read SEC document
October 08, 2020 Filed Oct 9, 2020 21:01 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	SaleClass A Common Stock	952	$288.00	$274,176.00	Disclosure SEC source: 0001209191-20-054497 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,183 Read SEC document
October 06, 2020 Filed Oct 8, 2020 20:25 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	50,000	$1.68	$83,985.00	Disclosure SEC source: 0001453687-20-000108 · wf-form4_160218871716347.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,013 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.675 to $1.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
September 25, 2020 Filed Sep 29, 2020 01:19 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	251	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052270 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752 Underlying: Class A Common Stock · 251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
September 25, 2020 Filed Sep 29, 2020 01:19 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	251	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052270 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document
June 25, 2020 Filed Jun 26, 2020 21:10 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	GrantRestricted Stock Units · Derivative	1,003	$0.00	$0.00	Disclosure SEC source: 0001209191-20-039114 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,003 Underlying: Class A Common Stock · 1,003 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F2 · derivative.exercise_date: The RSUs were granted under the Issuer's 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year, with 1/4 of the RSUs vesting on September 25, 2020, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service by the Reporting Person to the Issuer. F2 · derivative.expiration_date: The RSUs were granted under the Issuer's 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year, with 1/4 of the RSUs vesting on September 25, 2020, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service by the Reporting Person to the Issuer. Read SEC document
June 24, 2020 Filed Jun 26, 2020 20:21 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	Exercise / conversionCommon Warrants · Derivative	32,840	$0.13 Strike: $1.46	$4,105.00	Disclosure SEC source: 0001453687-20-000084 · wf-form4_159320286563017.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,840 shares Expires 2024-12-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 24, 2020 Filed Jun 26, 2020 20:21 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	Exercise / conversionCommon Stock	32,840	$1.46	$47,946.40	Disclosure SEC source: 0001453687-20-000084 · wf-form4_159320286563017.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 23, 2020 Filed Jun 24, 2020 20:45 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	SaleClass A Common Stock	347	$242.00	$83,974.28	Disclosure SEC source: 0001209191-20-038739 · doc4.xml · nonDerivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,884 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.9900 to $242.0700 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.